FOLLOW US

AstraZeneca China Obesity Drug Deal

America January 30, 2026

AstraZeneca China Obesity Drug Deal Worth Up to $18.5B

Biotechnology powerhouse AstraZeneca has inked a landmark licensing agreement with China’s CSPC Pharmaceutical Group Ltd., potentially worth $18.5 billion, aimed…

By Rihem Akkouche

Signup for the USA Herald
exclusive Newsletter